Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for heart failure symptoms in congenital heart disease with left-to-right shunt
IRCT20120520009801N11Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in Cardiovascular Malformation (CVM) and heart failure (HF) comparing Empagliflozin + standard therapy with Placebo + standard therapy (2 arms). Primary endpoints: Tricuspid regurgitation peak gradient, Left-to-right shunt gradient and 1 more. Started Mar 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
Cardiovascular Malformation (CVM)heart failure (HF)
Beyond the preview
Go deeper on IRCT20120520009801N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120520009801N11.